10.38

0.95% -0.10

Pre-market: 10.50 0.12 +1.16%

Fortrea Holdings Inc (FTRE)

Overview News Price History Option Chain Financials Why FTRE Down? Discussions Forecast

Fortrea Holdings Inc stock is traded at $10.38, with a volume of 1.35M. It is down -0.95% in the last 24 hours and down -35.37% over the past month. Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Previous Close:

$10.48

Open:

$10.48

24h Volume:

1.35M

Relative Volume:

0.85

Market Cap:

$959.11M

Revenue:

$2.98B

Net Income/Loss:

$-300.00M

P/E Ratio:

-3.0529

EPS:

-3.4

Net Cash Flow:

$225.00M

1W Performance:

+0.39%

1M Performance:

-35.37%

6M Performance:

-1.24%

1Y Performance:

-5.29%

1-Day Range:

$10.14

$10.76

1-Week Range:

$9.05

$11.11

52-Week Range:

$3.97

$18.67

Fortrea Holdings Inc Stock (FTRE) Company Profile

Name

Fortrea Holdings Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

877-495-0816

Address

8 MOORE DRIVE, DURHAM

Employee

14,500

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

FTRE's Discussions on Twitter

Compare FTRE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FTRE Fortrea Holdings Inc	10.38	968.35M	2.98B	-300.00M	225.00M	-3.40
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Fortrea Holdings Inc Stock (FTRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Upgrade	Truist	Hold → Buy
Jan-06-26	Upgrade	Evercore ISI	In-line → Outperform
Dec-15-25	Upgrade	Barclays	Underweight → Equal Weight
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Aug-04-25	Upgrade	Robert W. Baird	Neutral → Outperform
May-02-25	Initiated	Truist	Hold
Apr-10-25	Downgrade	Barclays	Equal Weight → Underweight
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Dec-06-24	Downgrade	Robert W. Baird	Outperform → Neutral
Sep-25-24	Downgrade	Jefferies	Buy → Hold
Aug-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jul-24-24	Resumed	Barclays	Equal Weight
Jun-06-24	Initiated	Goldman	Neutral
May-29-24	Initiated	TD Cowen	Hold
May-28-24	Initiated	Mizuho	Neutral
Mar-22-24	Initiated	Robert W. Baird	Neutral
Mar-06-24	Initiated	Deutsche Bank	Hold
Jan-05-24	Initiated	William Blair	Mkt Perform
Jan-04-24	Initiated	Jefferies	Buy
Dec-11-23	Upgrade	Citigroup	Neutral → Buy
Dec-01-23	Upgrade	Evercore ISI	In-line → Outperform
Nov-14-23	Upgrade	Barclays	Equal Weight → Overweight
Oct-19-23	Initiated	Citigroup	Neutral
Sep-14-23	Initiated	Evercore ISI	In-line
Aug-16-23	Initiated	Barclays	Equal Weight
Aug-07-23	Initiated	BofA Securities	Underperform

View All

Fortrea Holdings Inc Stock (FTRE) Latest News

Mar 04, 2026

Is Fortrea Holdings (FTRE) Now An Opportunity After A 38.4% Share Price Slide? - simplywall.st

Mar 04, 2026

S P Trends: How sensitive is Fortrea Holdings Inc to inflation2025 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn

Mar 04, 2026

Mar 03, 2026

Fortrea (FTRE) Q4 2025 Earnings Call Transcript - AOL.com

Mar 03, 2026

Q4 Earnings Highs And Lows: Fortrea (NASDAQ:FTRE) Vs The Rest Of The Drug Development Inputs & Services Stocks - Finviz

Mar 03, 2026

Mar 02, 2026